Partnerships

In addition to the vaccines developed in-house, we offer selected product candidates and technologies to third parties for commercial collaborations and co-development partnerships.

Currently, Intercell is involved in the development of vaccines with some of the global leading key players within the vaccine and pharmaceutical industry:

Indication	Partner
Japanese Encephalitis Virus (JEV) vaccine	Novartis / CSL / Biological E. Ltd.
S. aureus vaccine	Merck & Co., Inc.
Hepatitis C Virus (HCV) vaccine	Novartis
IC31® Seasonal Influenza vaccine	Novartis
Travellers' Diarrhea Vaccine Patch	GSK
Pandemic Influenza vaccine patch	GSK/HHS
Tuberculosis vaccine	Statens Serum Institut / sanofi-aventis
Pneumococcus vaccine	PATH
Group A Streptococcus vaccine	Merck & Co., Inc.
Bacterial vaccine (undisclosed indication)	sanofi-aventis
S. aureus antibodies	Merck & Co., Inc.
Pneumococcus antibodies	Kyowa Hakko Kirin

In addition, we have cooperative research and development agreements in place with:

The Centers for Disease Control and Prevention (Streptococcus pneumoniae vaccine)
The PATH Malaria Vaccine Initiative (Malaria vaccine)
The National Institutes of Health, U.S. Department of Health & Human Services